Judith E Karp, B Douglas Smith. Show Affiliations »
Abstract
Mesh： See more » Antineoplastic Agents/administration & dosageAntineoplastic Agents/pharmacologyApoptosis/drug effectsClinical Trials, Phase I as Topic/standardsCytarabine/administration & dosageCytarabine/pharmacologyDrug Resistance, NeoplasmHumansLeukemia, Myeloid, Acute/drug therapyNeural Tube Defects/drug therapyPyridines/administration & dosagePyridines/pharmacologyResearch DesignThiosemicarbazones/administration & dosageThiosemicarbazones/pharmacology
Substances： See more » Antineoplastic AgentsPyridinesThiosemicarbazonesCytarabine3-aminopyridine-2-carboxaldehyde thiosemicarbazone
Year: 2006 PMID： 16490252 DOI： 10.1016/j.leukres.2006.01.007
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156